IN ADULT PATIENTS WITH GENERALIZED PUSTULAR PSORIASIS (GPP)
SPEVIGO® has the power to treat GPP flares1
SPEVIGO® (spesolimab for injection) is indicated for the treatment of flares in adult patients with generalized pustular psoriasis (GPP).
![](/ca/products/spevigo/sites/default/files/2023-10/fire_flower_dragon.png)
In the EFFISAYIL-1 clinical trial, the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA), which ranges from 0 (clear) to 4 (severe), was used to assess the efficacy of SPEVIGO® (spesolimab for injection).
At Week 1, SPEVIGO® demonstrated efficacy in the primary and secondary endpoints vs. placebo:1*
![](/ca/products/spevigo/sites/default/files/2023-08/01-elements-placeholder-card-16-9_0.png)
HeadStartGo™ Program
Considering SPEVIGO®? Enroll your GPP patients into our HeadStartGo™ Program
![SPEVIGO® is a humanized antagonistic monoclonal IgG1 antibody that blocks IL-36R signalling¹*](/ca/products/spevigo/sites/default/files/2023-08/01-elements-placeholder-card-16-9%402x_0.png)
Mechanism of Action
The only IL-36 inhibitor indicated in the treatment of GPP flares1‡
![SPEVIGO® patient photos. A SPEVIGO® patient from the Effisayil-1 trial. Two images of a patient who received a single 900 mg IV dose of SPEVIGO®, following baseline assessment. This patient had a GPPGA pustulation subscore of 3 at baseline, and 0 at Week 1. Their GPPGA total score (a secondary endpoint) was 3 at baseline and 1 at Week 1.](/ca/products/spevigo/sites/default/files/2023-08/01-elements-placeholder-card-16-9_2.png)
Efficacy Data
IL-36=interleukin-36.
- *
- †
- ‡
![](/ca/products/spevigo/sites/default/files/2023-08/PAAB.png)